The advanced technologies in protein expression by Selexis provide biotech and pharmaceutical companies with a rapid, stable, and cost-effective solution for the production of recombinant proteins. Nearly a hundred drug candidates in clinical development and three commercial products utilize the technologies of the Plan-les-Ouates-based company.
Selexis was founded by Igor Fisch PhD and Professor Nicolas Mermod and launched as an academic spin-out from the University of Lausanne. Now based in Geneva, the company is a scientific pioneer and global leader in mammalian cell line generation.
At the time of the company's launch in 2001, average cell line development took more than a year and a half and the cells produced up to 1 gram/liter in a typical bioprocess. The introduction of the Selexis SUREtechnology Platform marked a real paradigm shift in biopharmaceutical drug development. By 2005, Selexis technology had reduced the mammalian cell line development time to just two months and boosted yield five-fold (up to 5 gram/liter).
Selexis, which is backed by Nobel Prize winner Sir Gregory Winter, has been granted more than 150 patents since 2001. More than 1,000 clonal research cell banks have been generated with the SUREtechnology platform in the areas of cancer, autoimmune/inflammatory diseases, blood disorders, metabolic disorders and dermatology/eye disorders.
In 2017, Selexis was acquired by the Japanese company JSR Corp. and integrated into its contract development and manufacturing division. Today the company boasts over 100 partners worldwide, more than 110 biologic drug development programs and four commercial products utilizing its cell lines and technologies. Selexis is a true Swiss success story. It has a history of empowering scientists and biopharmaceutical companies around the world to realise the full potential of their research and to improve the speed to market and economics for biologics and vaccines.
- Nominated in 2018
- Winner in 2019